Lantern Pharma Inc (LTRN)

Dec 10, 2024

AI-Powered Cancer Solutions: Lantern Pharma (LTRN) Launches Phase 2 Trial in Taiwan - Insider Monkey

Dec 10, 2024

Dec 09, 2024

Lantern Pharma starts dosing in Taiwan in non-smoker lung cancer trial - Yahoo Finance

Dec 09, 2024

Dec 09, 2024

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients - Business Wire

Dec 09, 2024

Dec 07, 2024

Lantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast Cancer - Yahoo Finance

Dec 07, 2024

Dec 06, 2024

15 AI News Updates That Broke The Internet - Insider Monkey

Dec 06, 2024

Dec 03, 2024

LTRNLantern Pharma Inc. Latest Stock News & Market Updates - StockTitan

Dec 03, 2024

Dec 03, 2024

Lantern Pharma Shares Rise After Fast-Track Designation for Cancer Treatment - Marketscreener.com

Dec 03, 2024

Dec 03, 2024

LP-184 gains FDA fast track for triple negative breast cancer - Investing.com

Dec 03, 2024

Dec 03, 2024

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC) - Eagle-Tribune

Dec 03, 2024

Nov 26, 2024

Lantern Pharma's LP-184 Shows 6x Better GBM Treatment Efficacy in Latest Trial Data | LTRN Stock News - StockTitan

Nov 26, 2024

Nov 26, 2024

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality - Business Wire

Nov 26, 2024

Nov 20, 2024

Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2024 Earnings Call Transcript - MSN

Nov 20, 2024

Nov 19, 2024

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients - BioSpace

Nov 19, 2024

Nov 19, 2024

Lantern Pharma stock hits 52-week low at $3.0 amid market challenges - Investing.com

Nov 19, 2024

Nov 19, 2024

Lantern Pharma's Lung Cancer Drug Shows 86% Benefit Rate, Expands to Japan Trial | LTRN Stock News - StockTitan

Nov 19, 2024

Nov 14, 2024

32BJ Health Fund Selects Lantern as Surgery Network Partner - GlobeNewswire Inc.

Nov 14, 2024

Nov 13, 2024

III: TechBio News Day 👾 - substack.com

Nov 13, 2024

Nov 12, 2024

LTRN: Pediatric Rare Cancer in Focus - Yahoo Finance

Nov 12, 2024

Nov 11, 2024

Earnings call: Lantern Pharma reports Q3 2024 financials and trial updates - Investing.com India

Nov 11, 2024

Nov 09, 2024

Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... By GuruFocus - Investing.com Canada

Nov 09, 2024

Nov 08, 2024

Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Stra - GuruFocus.com

Nov 08, 2024

Nov 08, 2024

Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... - Yahoo Finance

Nov 08, 2024

Nov 08, 2024

Lantern Pharma Advances AI-Driven Cancer Therapies - TipRanks

Nov 08, 2024

Nov 07, 2024

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates - BioSpace

Nov 07, 2024

Nov 05, 2024

Starlight Therapeutics Assembles Elite Brain Cancer Advisory Board, Backed by Top Oncologists | LTRN Stock News - StockTitan

Nov 05, 2024

Nov 05, 2024

Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth? - Simply Wall St

Nov 05, 2024

Nov 05, 2024

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board - Yahoo Finance

Nov 05, 2024

Oct 31, 2024

Non-Smokers Keep Getting Lung Cancer. Dallas’ Lantern Pharma Is Using AI to Fight Back - D Magazine

Oct 31, 2024

Oct 31, 2024

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET - BioSpace

Oct 31, 2024

Oct 29, 2024

Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development - ForexTV.com

Oct 29, 2024

Oct 23, 2024

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024 - Business Wire

Oct 23, 2024

Oct 21, 2024

Lantern Pharma to Host & Participate in Two Public Webinars During October - Business Wire

Oct 21, 2024

Oct 16, 2024

FDA grants Fast Track Designation to LP-184 for GBM treatment - Investing.com Canada

Oct 16, 2024

Oct 15, 2024

Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA - BioSpace

Oct 15, 2024

Oct 15, 2024

FDA Grants Fast Track Designation to LP-184 for Glioblastoma - OncLive

Oct 15, 2024

Oct 09, 2024

Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ... - Yahoo Finance

Oct 09, 2024

Oct 09, 2024

Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Prom - GuruFocus.com

Oct 09, 2024

Sep 30, 2024

After-Hour Surge: Lantern Pharma (LTRN) Shares Climb On Regulatory Approvals - Stocks Telegraph

Sep 30, 2024

Sep 26, 2024

11 Best AI Penny Stocks Under $10 in 2024 - CoinCodex

Sep 26, 2024

Sep 23, 2024

Lantern Pharma secures three new FDA rare disease tags - Investing.com

Sep 23, 2024

Sep 23, 2024

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers - BioSpace

Sep 23, 2024

Sep 23, 2024

Lantern Pharma Gets Three FDA Rare-Pediatric Designations for LP-184 - MarketWatch

Sep 23, 2024

Sep 11, 2024

Norton Cancer Institute patient receives first-in-world clinical trial medicine dose - Norton Healthcare

Sep 11, 2024

Aug 31, 2024

Lantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a Millionaire - Yahoo Finance

Aug 31, 2024